AGC acquires commercial manufacturing facility

By The Science Advisory Board staff writers

June 2, 2020 -- Contract development and manufacturing organization AGC Biologics has purchased a large-scale biopharmaceutical manufacturing facility in Boulder, CO.

The automated facility was previously owned by AstraZeneca and is well designed for high-volume commercial production, AGC noted. It contains two 20,000-liter stainless steel mammalian cell bioreactors with room for four additional bioreactors and has more than twenty acres for future expansion.

AGC Biologics
Image courtesy of AGC Biologics.

AGC plants to run full-scale operations at the new facility by April 2021. It will help the company advance a higher ratio of late-phase and commercial products and support a wider range of commercial demand, the company noted.

In addition, AGC will complete facility expansion projects in Seattle, Denmark, and Japan this year and in early 2021.

AGC to manufacture Takara Bio's COVID-19 vaccine
In the fight against COVID-19, AGC Biologics, a contract development and manufacturing organization, is partnering with Takara Bio to manufacture plasmid...
AGC Biologics, Faron to manufacture cancer immunotherapy
Contract development and manufacturing organization AGC Biologics has formed a cancer immunotherapy partnership with Faron Pharmaceuticals.
AGC Biologics, AdaptVac partner on COVID-19 vaccine
AGC Biologics, a contract development and manufacturing organization, and AdaptVac have teamed up to develop a COVID-19 vaccine.

Copyright © 2020 scienceboard.net


Conferences
Laboratory Products Association Annual Meeting
October 1-4
Scottsdale, Arizona United States
Cell & Gene Meeting on the Mesa
October 11-13
Carlsbad, California United States
IDWeek 2022
October 19-23
District of Columbia United States
American Society of Human Genetics Annual Meeting
October 25-29
Los Angeles, California United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter